Innorna to Present Advances in mRNA-LNP Therapies for PFIC2 and Wilson’s Disease at ASGCT 2025 Annual Meeting

BOSTON, HONG KONG & SHENZHEN – May 13, 2025 – Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced that it will present two posters at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28^th Annual Meeting. The presentations will highlight the company’s latest advancements in mRNA-based therapeutics, featuring LNP formulations with high efficiency and excellent safety profile for liver-targeted delivery to treat Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2) and Wilson’s Disease.

American Society of Gene & Cell Therapy (ASGCT) 28^th Annual Meeting

Date: May 13-17, 2025

Location: New Orleans, LA

Poster title: ABCB11 mRNA Therapy for The Treatment of Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2)

Poster number: 2033

Date: May 14, 2025

Time: 5:30 PM - 7:00 PM CT

Location: Poster hall

Poster title: ATP7B mRNA Therapy for The Treatment of Wilson’s Disease

Poster number: 1509

Date: May 15, 2025

Time: 5:30 PM - 7:00 PM CT

Location: Poster hall

About Innorna

Founded in 2019, Innorna is committed to developing state-of-the-art LNP delivery systems and RNA therapies to address unmet medical needs. Its proprietary Diversity-Oriented Lipid Library—with over 5,000 ionizable lipids—enables breakthroughs in mRNA vaccines, gene editing, and cell therapies.

With its innovative mRNA-LNP platform, Innorna has built a robust pipeline targeting infectious diseases, rare genetic disorders, and cancer immunotherapy. Beyond its internal R&D efforts, the company collaborates with global-leading biotechnology partners to expand the reach of its transformative technology.

Innorna’s achievements have earned recognition as one of MIT Technology Review’s Global Top 50 Smartest Companies and Fortune China’s Most Socially Influential Startups. Guided by INNOVATION, INTEGRITY, EFFICIENCY, and OPENNESS, Innorna drives its mission to revolutionize mRNA applications and make a global impact.